(Reuters) -AstraZeneca Plc said on Wednesday that China’s health regulator expanded the use of Tagrisso, the British drugmaker’s lung cancer treatment, in patients with a type of lung cancer when diagnosed at an early stage.
China’s National Medical Products Administration (NMPA) approved Tagrisso as an adjuvant therapy for patients with early-stage lung cancer who have a mutation of the EGFR gene, AstraZeneca said.
The drug is now approved to treat early-stage lung cancer in more than a dozen countries, including, most recently, in the United States.
The drugmaker said the Chinese approval was based on positive results from a late-stage trial that showed Tagrisso cut the risk of disease recurrence or death by 83%.
The EGFR mutation is found in about a quarter of global lung cancer cases, and older generation of EGFR inhibitors include Roche’s Tarceva and AstraZeneca’s own Iressa.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Shailesh Kuber)
